Featuring:

- **Premium and Enhanced Exhibits**
  Visit industry-sponsored exhibits to gather information and learn about new products.

- **NCCN Reimbursement Resource Room**
  Learn about reimbursement help and services available.

- **NCCN Patient Advocacy Pavilion**
  Gather information from a variety of patient advocates representing a range of disease types and patient support services.

- **Health Information Technology (HIT) Section**
  Visit and learn about decision support systems.

- **General Poster Sessions**
  View more than 200 posters accepted for the Annual Conference.

NCCN.org/Conference
A science-led global healthcare company with a special purpose

We are united around one goal – to be the world’s most innovative, best performing and trusted healthcare company. Our unique R&D approach fights cancer on multiple groundbreaking fronts – immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality.

We are committed to maximizing patient survival through transformational medicines and are passionate in our pursuit of innovative and effective treatments.

We believe in making cures a possibility.

us.gsk.com

©2021 GSK group of companies or its licensor. All rights reserved. PSE-US-0877. January 2022.
<table>
<thead>
<tr>
<th>Platinum Level Sponsors</th>
<th>Eisai Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GSK</td>
</tr>
<tr>
<td></td>
<td>Incyte</td>
</tr>
<tr>
<td>Gold Level Sponsors</td>
<td>Janssen Oncology</td>
</tr>
<tr>
<td></td>
<td>Pharmacyclics LLC., an AbbVie Company</td>
</tr>
<tr>
<td>Silver Level Sponsor</td>
<td>Regeneron</td>
</tr>
<tr>
<td>Bronze Level Sponsors</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td></td>
<td>BeiGene</td>
</tr>
<tr>
<td></td>
<td>Jazz Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Servier Pharmaceuticals</td>
</tr>
<tr>
<td>Patient Advocacy Pavilion Sponsors</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Ruby</strong></td>
<td></td>
</tr>
<tr>
<td>Pharmacyclics LLC., an AbbVie Company</td>
<td></td>
</tr>
<tr>
<td><strong>Emerald</strong></td>
<td></td>
</tr>
<tr>
<td>AstraZeneca</td>
<td></td>
</tr>
<tr>
<td>BeiGene</td>
<td></td>
</tr>
<tr>
<td>Coherus BioSciences</td>
<td></td>
</tr>
<tr>
<td>Eisai Inc.</td>
<td></td>
</tr>
<tr>
<td>Gilead &amp; Kite Oncology</td>
<td></td>
</tr>
<tr>
<td>Incyte</td>
<td></td>
</tr>
<tr>
<td>Janssen Oncology</td>
<td></td>
</tr>
<tr>
<td>Karyopharm Therapeutics, Inc.</td>
<td></td>
</tr>
<tr>
<td><strong>Topaz</strong></td>
<td></td>
</tr>
<tr>
<td>AbbVie</td>
<td></td>
</tr>
<tr>
<td>Amerisource Bergen</td>
<td></td>
</tr>
<tr>
<td>GSK</td>
<td></td>
</tr>
<tr>
<td>Heron Therapeutics, Inc.</td>
<td></td>
</tr>
<tr>
<td>Lantheus</td>
<td></td>
</tr>
<tr>
<td><strong>Jade</strong></td>
<td></td>
</tr>
<tr>
<td>Servier Pharmaceuticals</td>
<td></td>
</tr>
</tbody>
</table>
Together with GSK Oncology offers a variety of access and reimbursement services in one location for all GSK oncology products.

**Reimbursement support**

- Insurance benefits investigation
- Information about prior authorizations
- Guidance on insurance denials or coverage requirements
- Coding and claims assistance for products and related services

*Together with GSK Oncology does not guarantee coverage or payer reimbursement for product treatment or administration. Healthcare professionals should confirm information directly with payers.*

**Access assistance**

- Co-pay assistance for eligible commercially insured patients
- Patient assistance program that makes free product available to eligible patients
- Information about alternative funding sources

For program terms and eligibility and to obtain a *Together with GSK Oncology* Enrollment Form, visit TogetherWithGSKOncology.com or call 1-844-4GSK-ONC (1-844-447-5682), Monday-Friday, (8AM to 8PM ET)

Connect with *Together with GSK Oncology* today
All attendees are invited to visit these booths via access through the Digitell platform. All registered attendees can use the log-in information provided for access to the conference.
Pharmacyclics Medical Affairs Provides Balanced, Scientific, And Evidence-Based Information

The Pharmacyclics Medical Affairs team remains committed to providing balanced, scientific information, available in person or virtually

Pharmacyclics Medical Affairs provides non-promotional educational programs on approved Pharmacyclics products and supported disease states, including:

- **Disease state education**
- **Product clinical overview, including efficacy, safety, and adverse event management**
- **Clinical trial design overview**

Pharmacyclics Medical Affairs provides balanced and evidence-based scientific answers to your questions. To submit your medical information questions or find your local MSL, please visit [www.PharmacyclicsMedInfo.com](http://www.PharmacyclicsMedInfo.com)
Scientific Information, Medical Inquiries, and Research Support Are Available to You

Pharmacyclics MSLs provide our medical community with timely, comprehensive medical information as data updates from national and regional conferences on approved Pharmacyclics products and relevant disease states.

Pharmacyclics assists current clinical research sites for company-sponsored trials with continued education of the study team on the study design, protocol activities, and data read-outs.

Request a Medical Science Liaison

Scan the QR code or visit https://www.pharmacyclicsmedinfo.com/medical-science-liaison.html to find a representative in your area.
| Thursday, March 31  
12:05 - 12:35 PM EDT | Clinical Profile of a PARP Inhibitor for the Treatment of mCRPC  
*Presented by AstraZeneca* |
|-----------------------|------------------------------------------------------------------|
| Thursday, March 31  
4:30 - 5:00 PM EDT   | Exploring the Advancements in the Treatment of HER2+ Unresectable or Metastatic Breast Cancer  
*Presented by Daiichi Sankyo, Inc. and AstraZeneca* |
| Friday, April 1  
10:00 - 10:30 AM EDT | Adult Immunizations: Injection Helps Protection!  
*Presented by GSK* |
| Friday, April 1  
12:05 - 12:35 PM EDT | Learn More About an FDA-Approved Treatment for Metastatic Triple-Negative Breast Cancer  
*Presented by Gilead* |
| Friday, April 1  
4:30 - 5:00 PM EDT   | Dosing and Adverse Reaction Management for LENVIMA® (lenvatinib): Abbreviated Program  
*Presented by Eisai* |
| Saturday, April 2  
10:00 - 10:30 AM EDT | Explore Data for an FDA-approved Treatment Option in HR+, HER2- Breast Cancer in Certain Adjuvant or Metastatic Settings  
*Presented by Lilly* |
Is it time to intervene?

Visit hcp.jakafi.com to learn more

SCAN to visit hcp.jakafi.com
REACH FOR
MONJUVI®
tafasitamab-cxix | 200mg
for injection, for intravenous use

For more information and resources:
Visit MonjuviHCP.com
Is PEMAZYRE a treatment option for your patients?

To learn more, visit www.hcp.pemazyre.com
Explore the clinical profile of LIBTAYO across a number of difficult-to-treat diseases

Visit LIBTAYOhcp.com to learn more
About Our Exhibitors

Astellas Pharma US
Astellas Pharma US, Inc. is a U.S. affiliate of Tokyo-based Astellas Pharma Inc., a pharmaceutical conducting business in more than 70 countries around the world. Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.

AstraZeneca – Bronze Sponsor
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

Bristol Myers Squibb
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

Gilead Oncology — Commercial
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved milestones in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to developing and advancing innovative medicines to prevent and treat life-threatening diseases. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.

Incyte – Platinum Sponsor
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Pfizer Oncology
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, genitourinary, colorectal, blood and lung cancers, as well as melanoma.
### About Our Exhibitors

**ENHANCED EXHIBITS**

**AbbVie**
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at [www.abbvie.com](http://www.abbvie.com). Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

**Acrotech Biopharma LLC**
Founded in 2018, Acrotech Biopharma, was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech Biopharma aspires to be a patient focused, research-based organization that strives to launch treatments which are accessible to patients that need them.

**BeiGene – Bronze Sponsor**
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. We currently market an internally discovered product in the United States, BRUKINSA® (zanubrutinib).

**Deciphera Pharmaceuticals**
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing new medicines to improve the lives of people with cancer. We leverage our clinical-stage proprietary switch-control kinase inhibitor platform and expertise in kinase biology to develop a broad portfolio of innovative medicines. QINLOCK® is our first FDA-approved product for eligible advanced GIST patients who have received 3 prior TKIs, including imatinib. Please see below for Important Safety Information and full Prescribing Information for QINLOCK.

**EUSA Pharma**
EUSA Pharma is a global biopharmaceutical committed to transforming lives affected by cancer or rare disease. We continuously strive to uncover opportunities which address gaps across adult and pediatric care. Helping people with few or no options available is at the heart of everything we do at EUSA. We Change Lives, Patient by Patient.

**G1 Therapeutics**
Our mission is to develop and deliver innovative therapies that improve the lives of adults living with cancer. G1 is currently commercializing the Company's first FDA-approved product, COSELA™ (trilaciclib), designed to improve outcomes for adults with extensive-stage small-cell lung cancer who are receiving chemotherapy. G1 is also executing a tumor-agnostic development program evaluating COSELA in combination with multiple treatment types and across multiple tumor types, including colorectal, breast, and bladder cancers.

**Gilead Oncology – Medical Affairs**
Gilead is creating the future of oncology to help bring more life to people with cancer. We are focused on delivering transformational science, maximizing speed to the patient, and being a partner of choice.

**GSK – Platinum Sponsor**
GSK is focused on maximizing patient survival through transformational medicines. GSK’s oncology pipeline is focused on immuno-oncology, oncology cell therapy, tumor cell targeting and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.
About Our Exhibitors

Harborside
Harborside is the foremost medical communications company that oncology clinicians turn to for accurate content, news, and education. The company is the publisher of *JNCCN—Journal of the National Comprehensive Cancer Network*, *The ASCO Post*, and *Journal of the Advanced Practitioner in Oncology*. Harborside also manages the advertising sales for ASCO's suite of publications—the *Journal of Clinical Oncology (JCO)*, *JCO Oncology Practice*, *JCO Global Oncology*, *JCO Clinical Cancer Informatics*, and *JCO Precision Oncology*.

Helsinn
Helsinn is a privately owned pharmaceutical group headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland, the U.S. and a representative office in China. Helsinn is one of the world's leading supportive cancer care companies. Our portfolio of products combines therapies we license and therapies developed at Helsinn. [www.helsinn.com](http://www.helsinn.com)

Janssen Biotech, Inc. – Gold Sponsor
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working for patients everywhere fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart.

Jazz Pharmaceuticals – Bronze Sponsor
At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.

Karyopharm Therapeutics, Inc.
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs for the treatment of cancer and other diseases. Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.

Regeneron and Sanofi – Silver Sponsor
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit [www.regeneron.com](http://www.regeneron.com) or follow @Regeneron on Twitter.

Sanofi
Sanofi is an innovative global healthcare company. We are working to advance transformative therapies to help people with cancer. Our current focus is on multiple myeloma and other blood cancers, skin, prostate, lung, and breast cancers. We take bold steps every day to advance our pipeline and work to find solutions that help address critical gaps in care across a variety of difficult-to-treat cancers.

Sema4
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis®, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness to provide science-driven solutions to the most pressing medical needs.
Servier Pharmaceuticals – Bronze Sponsor
Servier Pharmaceuticals is a commercial-stage pharmaceuticals company with a passion for innovation and improving the lives of patients, their families and caregivers. In the United States, Servier Pharmaceuticals is committed to building a robust portfolio, starting with oncology, with future growth driven by innovation in other areas of unmet medical need, leveraging Servier’s global portfolio and seeking acquisitions, licensing deals and partnerships.

Sun Pharma
Sun Pharma is the 4th largest specialty generic pharmaceutical company in the world, providing high-quality, affordable medicines in over 150 countries. Our mission is to enhance people’s lives with innovative and quality generic, branded, and over-the-counter medicines, providing exceptional value in our communities. In the US, Sun Pharma is focused on helping patients in Generics, Dermatology, Oncology, Ophthalmology, and Long Term Care.

Taiho Oncology
The mission of Taiho Oncology is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in orally administered anti-cancer agents and has a growing pipeline of antimetabolic and selectively targeted anti-cancer agents. A subsidiary of Taiho Pharmaceutical Co., Ltd., Taiho markets its medicines for a range of tumor types in the U.S. and oversees its parent company’s European and Canadian operations in Zug, Switzerland and Oakville, Ontario, Canada.

NCCN Virtual Reimbursement Resource Room
Reimbursement help and services available to patients with cancer navigating the oncology landscape.

NCCN.org/reimbursement
Patient Advocacy Pavilion

Anal Cancer Foundation

The Anal Cancer Foundation is dedicated to empowering anal cancer patients and accelerating prevention and treatment methods that eliminate anal cancer and the virus that causes most cases, HPV.

Specifically, our mission is to:
• Highlight the relevance of HPV in cancer
• Accelerate a cure for the 5% of all cancers caused by HPV, focusing on anal cancer
• Advocate for prevention methods that will end HPV-related cancers, including vaccination
• Support survivors, caregivers, scientists, and providers

Bag It

Bag It educates, supports and empowers patients, caregivers & advocates through two programs. The Bag It bag has information & a navigation binder to help patients organize medical records, cope with a diagnosis and advocate for their best quality of care. Escape to THRIVE is a national leadership conference for cancer advocates focusing on personal well-being and professional learning.

Cancer Support Community

The Cancer Support Community is a global non-profit network of 175 locations, including CSC and Gilda's Club centers, hospital and clinic partnerships, and satellite locations that deliver free support and navigation services to patients and families. We administer a toll-free helpline and produce award-winning educational and digital resources that reach more than one million people each year, conduct cutting-edge research on the patient journey, and advocate for policy change at all levels of government.

The Cholangiocarcinoma Foundation

The Cholangiocarcinoma Foundation is a global 501(c)(3) non-profit organization headquartered in Utah. Its mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (bile duct cancer). The Foundation achieves that mission by providing resources, advocacy for patients, collaborations within the scientific and medical community, and educating an international audience about this lethal cancer.

CLL Society

CLL Society is an inclusive, patient-centric, physician-curated nonprofit organization that addresses the unmet needs of the chronic lymphocytic leukemia (CLL) community through patient education, advocacy, support, and research. We explain the rapidly changing therapeutic landscape and the importance of clinical trials, build patient support networks, engage in research, and educate providers and patients. We believe SMART PATIENTS GET SMART CARE™. Learn more at cllsociety.org.

FREE CLL/SLL Patient Education Toolkit

The CLL Society CLL/SLL Patient Education Toolkit is a professionally designed binder featuring pull-out sheets on dozens of topics that will provide your patients with just-in-time information to reinforce the education and care you are already providing. Each binder has a take-home paper version of the best available information pertinent to the current state of their CLL journey. This is a free resource for healthcare providers.

To sign-up, please visit “Sign-up for a free CLL/SLL Patient Education Toolkit” linked in our Resources.

Colorectal Cancer Alliance

Colorectal Cancer Alliance is the leading national nonprofit committed to ending colorectal cancer within our lifetime. We empower a nation of passionate survivors and advocates to help patients and caregivers navigate diagnosis and treatment, and we serve as allies with healthcare professionals—those who understand the value of early detection. Partnering with doctors and nurses around the country, we are working urgently to raise awareness of preventive screening because we believe tomorrow can’t wait.

The Foundation for Women’s Cancer

The Mission of the Foundation for Women’s Cancer is to bring together all communities of advocates, patients, caregivers, partners and the healthcare team to eradicate or lessen the impact of gynecologic cancer. We will achieve this through research, education and public awareness to create a world where everyone has the power to impact, prevent or overcome a diagnosis of gynecologic cancer.
GO2 Foundation for Lung Cancer

GO2 Foundation transforms survivorship by working across the entire continuum of care for those who are at-risk or diagnosed with lung cancer.

Ways to support patients and care partners:
• Helpline- 1:1 support by phone, email, and website
• LungMATCH- Treatment and trial navigation
• Phone Buddy Program- Peer to peer matching
• Lung Cancer Living Room Series- A three-part program providing educational and support opportunities to learn, ask questions, and connect
• Online communities (Health Unlocked and Belong)
• Free educational publications on a wide variety of topics

HealthTree Foundation

The HealthTree Foundation has built many patient programs and over 8 integrated software platforms to help blood cancer patients learn more about their disease and better navigate their disease. Patients can find a coach, stay updated with news in patient-friendly language, find crowdsourced side effect solutions, see personalized clinical trials and treatment options, listen to podcasts, join community forums and educational live and online meetings, learn from experts in HealthTree University and so much more.

The Leukemia & Lymphoma Society (LLS)

The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services. www.LLS.org/PatientSupport

The Lymphoma Research Foundation

The Lymphoma Research Foundation is the nation’s largest non-profit organization devoted exclusively to funding lymphoma research and supporting the lymphoma community through evidence-based education, support services, and resources. The Foundation’s mission is to eradicate lymphoma and serve those touched by this disease by sharing research and treatment insights directly with the lymphoma community through national education programs and resources.

MDS Foundation

MDS Foundation supports and educates patients, their communities, and healthcare providers, and contributes to innovative research in the fields of MDS and its related continuum of diseases to better diagnose, control and ultimately cure these diseases. patients and their families as well as healthcare The MDS Foundation is a global non-profit advocacy organization that for over 25 years has supported patients and their families as well as healthcare providers in the fields of MDS and its related diseases.

Sharsheret

Sharsheret is a national non-profit organization that supports women and families facing breast or ovarian cancer, or who are at higher diagnostic risk. Our free, confidential support includes access to social workers, a genetic counselor, and a range of support programs, including financial subsidies, to help women navigate their cancer experiences. Sharsheret has educational brochures to share with patients and free, CME approved, professional training for your team. For more information/to order resources, email mrosen@sharsheret.org.

Triage Cancer

Triage Cancer provides education on legal and practical issues that may impact individuals diagnosed with cancer and their caregivers. Provides expert content on issues related to work, insurance, disability benefits, finances, estate planning, medical decision-making, and more. Offers free in-person and online educational events, materials, animated videos, and state-specific resources. Provides free on-on-one help to assist individuals understand their options and possible next steps, as well as CancerFinances.org, which helps people navigate finances after cancer.
Health Information Technology (HIT) Section

Flatiron Health
Flatiron Health® is a healthtech company that marries clinical and data science to improve outcomes for cancer patients today and tomorrow. We translate patient experiences into real-world evidence to advance research and inform policy.

Optum
The Optum® Cancer Guidance Program (CGP) is an evidence-based utilization management and analytics service for medical oncology treatments. This comprehensive solution includes an online portal that helps providers obtain authorizations quickly and easily, is guided by 100+ oncology clinicians, and supports 27M+ members today.

SAVE THE DATES!
Friday, March 31, 2023 – Sunday, April 2, 2023

NCCN Annual Conference 2023
March 31 - April 2
Orlando World Center Marriott | Orlando, FL
Virtual option also planned
NCCN.org/conference
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

gsk.com
Ripretinib (QINLOCK®) is THE ONLY therapy recommended for 4th-line advanced GIST by the National Comprehensive Cancer Network® (NCCN®)²

FOR ADVANCED GIST PATIENTS TREATED WITH ≥3 PRIOR TKIs

BREAK THROUGH RESISTANCE

Choose QINLOCK, the first and only switch-control kinase inhibitor for advanced GIST¹

Approved for patients regardless of mutation, including¹:

✔ KIT
✔ PDGFRα
✔ WILD TYPE

The most common adverse reactions (>35%) include alopecia, fatigue, nausea, and abdominal pain.

The safety and effectiveness of QINLOCK in pediatric patients have not been established.

Administer strong CYP3A inhibitors with caution. Avoid concomitant use with strong and moderate CYP3A inducers. If a moderate CYP3A inducer cannot be avoided, increase QINLOCK dosing frequency from the recommended dose of 150 mg once daily to 150 mg twice daily during the co-administration period.

Please see Brief Summary of Prescribing Information following. Please see additional complete Safety Information and full Prescribing Information including Patient Information, at QINLOCKHCP.com.

To report SUSPECTED ADVERSE REACTIONS, contact Deciphera Pharmaceuticals, LLC, at 1-888-724-3274 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References: 1. Qinlock [package insert]. Waltham, MA: Deciphera Pharmaceuticals, Inc; 2021. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology. (NCCN Guidelines®) for Gastrointestinal Stromal Tumors (GISTs) V1.2021 ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Published October 30, 2020. Accessed October 30, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

GIST=gastrointestinal stromal tumor; KIT=KIT proto-oncogene receptor tyrosine kinase; PDGFRα=platelet-derived growth factor receptor α; TKI=tyrosine kinase inhibitor.
INDICATION: QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

DOSEAGE AND ADMINISTRATION: Recommended dosage: 150 mg orally once daily with or without food. Advise patients to swallow tablets whole. Inform patients about what to do in the event they miss a dose or vomit after taking a dose of QINLOCK. If a moderate CYP3A inducer cannot be avoided, increase QINLOCK dosing frequency from the recommended dose of 150 mg once daily to 150 mg twice daily during the co-administration period. If the concomitant moderate CYP3A inducer is discontinued, resume QINLOCK dosing back to 150 mg once daily 14 days after the discontinuation of the moderate CYP3A inducer.

CONTRAINdications: None

WARNINGs AND PRECAUTIONS:

Palmar-Plantar Erythrodysesthesia Syndrome (PPES) - In INVICTUS, Grade 1-2 palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 21% of the patients who received QINLOCK. PPES led to dose discontinuation in 1.2% of patients, dose interruption in 2.4% of patients, and dose reduction in 1.2% of patients. Based on severity, withhold QINLOCK and then resume at same or reduced dose.

New Primary Cutaneous Malignancies - In INVICTUS, cutaneous squamous cell carcinoma (cuSCC) occurred in 4.7% of the 85 patients who received QINLOCK, with a median time to event of 4.6 months (range: 3.8 to 6 months). In the pooled safety population, cuSCC and keratoacanthoma occurred in 7% and 1.9% of 351 patients, respectively. In INVICTUS, melanoma occurred in 2.4% of the 85 patients who received QINLOCK. In the pooled safety population, melanoma occurred in 0.9% of 351 patients.

Perform dermatologic evaluations when initiating QINLOCK and routinely during treatment. Manage suspicious skin lesions with excision and dermatopathologic evaluation. Continue QINLOCK at the same dose.

Hypertension - In INVICTUS, Grade 1-3 hypertension occurred in 14% of the 85 patients who received QINLOCK, including Grade 3 hypertension in 7%. Do not initiate QINLOCK in patients with uncontrolled hypertension. Adjustly control blood pressure prior to initiating QINLOCK. Monitor blood pressure as clinically indicated during treatment with QINLOCK and initiate or adjust antihypertensive therapy as appropriate. Based on severity, withhold QINLOCK and then resume at same or reduced dose or permanently.

Cardiac Dysfunction - In INVICTUS, cardiac failure occurred in 1.2% of the 85 patients who received QINLOCK. In the pooled safety population, cardiac dysfunction (including cardiac failure, acute left ventricular failure, diastolic dysfunction, and ventricular hypertrophy) occurred in 1.7% of 351 patients, including Grade 3 adverse reactions in 1.1%.

In INVICTUS, Grade 3 decreased ejection fraction occurred in 2.6% of the 77 patients who received QINLOCK who had a baseline and at least one post-baseline echocardiogram. In the pooled safety population, Grade 3 decreased ejection fraction occurred in 3.4% of the 263 patients who received QINLOCK and who had a baseline and at least one post-baseline echocardiogram.

In INVICTUS, cardiac dysfunction led to dose discontinuation in 1.2% of the 85 patients who received QINLOCK. The safety of QINLOCK has not been assessed in patients with a baseline ejection fraction below 50%. Assess ejection fraction by echocardiogram or MUGA scan prior to initiating QINLOCK and during treatment, as clinically indicated. Permanently discontinue QINLOCK for Grade 3 or 4 left ventricular systolic dysfunction.

Risk of Impaired Wound Healing - Impaired wound healing complications can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, QINLOCK has the potential to adversely affect wound healing.

Withhold QINLOCK for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of QINLOCK after resolution of wound healing complications has not been established.

Embryo-Fetal Toxicity - Based on findings from animal studies and its mechanism of action, QINLOCK can cause fetal harm when administered to a pregnant woman.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with QINLOCK and for at least 1 week after the final dose.

ADVERSE REACTIONS:

Serious adverse reactions occurred in 31% of patients who received QINLOCK. Serious adverse reactions that occurred in ≥2% of patients were abdominal pain (4.7%), anemia (3.5%), nausea (2.4%), and vomiting (2.4%).

The most common adverse reactions (≥20%) were alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, PPES, and vomiting. The most common Grade 3 or 4 laboratory abnormalities (≥4%) were increased lipase and decreased phosphate. Clinically relevant adverse reactions that occurred in ≤10% of patients in the pooled safety population included cardiac ischemic events (cardiac arrest, acute coronary syndrome, and myocardial infarction), which occurred in 1.1% of patients. Of these, cardiac arrest and myocardial infarction were reported as fatal adverse reactions.

Peripheral permanent discontinuation due to an adverse reaction occurred in 8% of patients who received QINLOCK. Adverse reactions resulting in permanent discontinuation in ≥1% of patients included general physical health deterioration (2.4%), anemia (1.2%), cardiac failure (1.2%), PPES (1.2%), and vomiting (1.2%).

Dosage interruptions due to an adverse reaction occurred in 24% of patients who received QINLOCK. Adverse reactions resulting in a dose reduction in ≥1% of patients were abdominal pain, agitation, alopecia, arthritis, dermatosis, gastrointestinal disorder, hyperesthesia, myalgia, PPES, and decreased weight.

DRUG INTERACTIONS:

Coadministration of QINLOCK with strong CYP3A inhibitors may increase the risk of adverse reactions. Monitor patients more frequently for adverse reactions. Avoid concomitant use of QINLOCK with strong and moderate CYP3A inducers.

USE IN SPECIFIC POPULATIONS:

Pregnancy - see Embryo-Fetal Toxicity

Lactation - Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with QINLOCK and for at least 1 week after the final dose.

Females and Males of Reproductive Potential - QINLOCK can cause fetal harm when administered to a pregnant woman. Verify pregnancy status of females of reproductive potential prior to the initiation of QINLOCK. Advise females of reproductive potential to use effective contraception during treatment and for at least 1 week after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for at least 1 week after the final dose. Based on findings from animal studies, QINLOCK may impair fertility in males of reproductive potential.

Pediatric Use - The safety and effectiveness of QINLOCK in pediatric patients have not been established.

Geriatric Use - Clinical studies of QINLOCK did not include sufficient numbers of patients aged 65 and older to determine whether they respond differently from younger patients.

Hepatic Impairment - No dose adjustment is recommended in patients with mild hepatic impairment (total bilirubin ≤ULN and AST > ULN or total bilirubin 1 to 1.5 × ULN and AST any). A recommended dosage of QINLOCK has not been established for patients with moderate or severe hepatic impairment.

NONCLINICAL TOXICOLOGY:

Carcinogenesis, Mutagenesis, Impairment of Fertility - Carcinogenicity studies have not been conducted with ripretinib.

To report SUSPECTED ADVERSE REACTIONS, contact Deciphera Pharmaceuticals, LLC, at 1-888-724-3274 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Manufactured for and marketed by: Deciphera Pharmaceuticals, LLC

200 Smith Street, Waltham, MA 02451

© 2021 Deciphera Pharmaceuticals. The QINLOCK® word mark and logo are registered trademarks of Deciphera Pharmaceuticals, LLC, Deciphera, Deciphera Pharmaceuticals, and the Deciphera logo are trademarks of Deciphera Pharmaceuticals, LLC. All rights reserved. DCPH-POOS80 07/21
Our mission is patients first through science and affordability. To help transform the biotechnology industry, creating impactful medicines that will be affordable and accessible to far more cancer patients around the world through science and business innovation.

- **8,000+** employees (as of January 2022)
- **30+** filed or potentially registration enabling trials ongoing, **95+** studies in **40+** geographies
- **~50** commercial or clinical stage assets
- **30** offices on **5** continents
- **20+** filings accepted for **10** medicines in over **50** geographies, including 2nd drug in U.S. and first in E.U.
- **9** approved medicines, including **1** in the US

Website: BeiGene.com
Twitter: @BeiGeneGlobal
LinkedIn: linkedin.com/company/beigene
Adult Immunizations: Injection Helps Protection!

Friday, April 1, 2022 | 10:00 AM – 10:30 AM

SPEAKERS

Daniel Verdi, MD
GSK Medical Affairs
Senior Director

Lauren Wilson, PharmD
GSK Medical Affairs
Scientific Director

Adult immunization rates during the pandemic continue to lag.
Rates were already suboptimal leading into the pandemic decline. This presentation will explore current immunization rates, Healthy People 2030 goals, guideline overviews, and other key information to help inform and educate patients around value of this preventive measure.
MOVING RESEARCH INTO PRACTICE

Read by QxMD is a mobile first, personalized medical & scientific journal that allows busy oncologists to keep up with the latest new research that impacts their practice in minutes per day.

Read is integrated with full text holdings at thousands of institutions around the globe, including Harvard, Yale and the Massachusetts General Hospital.

Available for iPhone, iPad, Android tablets & smartphone, and the web.

Click to get Read now!
Click for the Read Institutional Edition!
For 40 years, the Cancer Support Community (CSC) has been a relentless ally for anyone impacted by cancer, delivering more than $50 million in free support services to patients and families, in-person, online, or over our toll-free helpline. CSC helps individuals manage the realities of this disruptive disease and get back to living.

CSC produces award-winning educational resources including booklets, worksheets, videos, and podcasts - all of which are available for free.
Dear Health Care Provider,

The CLL Society is pleased to offer you a CLL-specific PATIENT EDUCATION TOOLKIT, free of charge.

To preview the ToolKIT content you’ll receive in the mail, go to: cllsociety.org/kit

Please note that the actual ToolKIT contains multiple copies of handouts on each topic, allowing you to share time-appropriate information with your patients.

Order your free copy online to share with patients at cllsociety.org/patient-education-toolkit-registration/. We’ll mail your ToolKIT and email you when updates are available.

- Curated, patient-friendly content written by CLL experts
- Supplements your patient education
- Patients leave your office with the specific handouts you choose
- Easy to download replacement pages when supplies run low
- Materials are updated whenever the therapeutic or regulatory landscape changes

llsociety.org

A blood cancer diagnosis can be overwhelming for your patients. Blood cancer patients, including those with leukemia, lymphoma and myeloma, can find hope, education, guidance and support from The Leukemia & Lymphoma Society (LLS).

Our Information Specialists complement the care you provide with FREE, in-depth personalized services that connect patients to financial assistance, patient education (including booklets, podcasts and webinars), online and in-person support, and the LLS Clinical Trial Support Center for assistance with clinical trials.

Patients and families can contact us at 800.955.4572 or go to www.LLS.org/patient-support.
Colorectal cancer is the second-leading cause of cancer-related deaths in the U.S.

We are a nation of passionate allies determined to end this senseless killer.

Join us at NationOfAllies.org

(877) 422-2030
Questions about ALL treatments? Our Nurse Educators have answers.

Our Oncology Nurse Educators can provide information about PEGylated asparaginases.

Learn about the following:
- Treatment options
- Disease state
- Minimal residual disease
- Toxicity management
- Supportive care

Schedule a Call

Did You Know? The Myelodysplastic Syndromes (MDS) Foundation, Inc. was established by an international group of physicians and researchers to provide an ongoing exchange of information relating to MDS.

Until the Foundation was set up, no formal working group had been devoted to MDS. Since its inception, we have conducted 15 international symposia in Austria, England, the United States (Chicago, Washington, DC), Spain (Barcelona, Valencia), Czech Republic, Sweden, France, Japan, Italy, Greece, Scotland, and Germany. The 16th International Congress will be held in Toronto, Canada on September 23-26, 2021.

A major MDS Foundation effort is our international information network. This network provides patients with referrals to Centers of Excellence, contact names for available clinical trials, sharing of new research and treatment options between physicians, and extension of educational support to physicians, nurses, pharmacists and patients.

In response to the needs expressed by patients, families, and healthcare professionals, we have established patient advocacy groups, research funding, and professional educational initiatives.

The MDS Foundation is a publicly supported organization, exempt from federal income tax under section 501(C)(3) of the IRS code.

Learn more about The Myelodysplastic Syndromes Foundation, Inc. and find additional resources here: www.mds-foundation.org
Join the Foundation for Women’s Cancer to #MoveTheMessage

With this campaign, our goal is to increase awareness of gynecologic cancers, starting with historically marginalized communities, through dissemination of critical patient education resources.

Educational materials available for download @ MovetheMessage.org

---

Your trusted partner in strengthening cancer care

Learn more:
flatiron.com/oncology/clinical-decision-support/
Finding Cures,  
Fostering Hope.

Each year, the Lymphoma Research Foundation serves more than two million patients and their loved ones through education programs, resources, and support services. As the nation’s largest lymphoma-focused health organization, we’re also committed to funding the most promising lymphoma researchers and advancing the understanding of the more than 100 different subtypes of lymphoma.

Finding cures starts here.

ACF | ANAL CANCER FOUNDATION

Peer-to-Peer Support Program

A free service from the Anal Cancer Foundation matching anal cancer patients across the US and their caregivers with peer volunteers.

Refer your patients and learn more:
Connect@AnalCancerFoundation.org
AnalCancerFoundation.org

The Anal Cancer Foundation is dedicated to empowering anal cancer patients and accelerating prevention and treatment methods that eliminate anal cancer and HPV.
Triage Cancer Insurance & Finance Intensive

Join us for a free, comprehensive training designed specifically for oncology health care professionals and advocates.

- FREE continuing education
- Online & in-person trainings throughout the year
- Learn to help patients and caregivers navigate the financial impact of a cancer diagnosis

Register Today!

TriageCancer.org/Intensive

What’s in the bag:

- Top resource publications
- A customizable My Companion Guidebook that helps patients organize and access their medical information

What the bag means to your practice:

- Saves time and costs by compiling resources into a single toolkit
- Helps practices meet accreditation guidelines
- Improves patient adherence to treatment and supports better outcomes

Patient education focusing on self-advocacy and survivorship through the continuum of care
PHENPath supports patients in making informed and shared-decisions with their doctors by:

- Helping patients understand their cancer risk level when newly diagnosed
- Providing a comprehensive overview of treatment options for patients
- Offering prostate cancer information, resources and patient education

Visit PHENPath.com to gain an understanding of treatment options along your prostate cancer journey.

SAVE THE DATE

New York Marriott Marquis • New York, New York
Friday, October 14, 2022 – Saturday, October 15, 2022
NCCN Guidelines for Patients

Access 60+ FREE cancer resources

Acute Lymphoblastic Leukemia (adult)
Acute Lymphoblastic Leukemia (pediatric)
Acute Myeloid Leukemia
Adolescents and Young Adults with Cancer
Anal Cancer
Anemia and Neutropenia - Low Red and White Blood Cell Counts
Basal Cell Skin Cancer
B-Cell Lymphomas - Diffuse Large B-Cell Lymphoma
B-Cell Lymphomas - Follicular Lymphoma
B-Cell Lymphomas - Mantle Cell Lymphoma
Bladder Cancer
Bone Cancer
Brain Cancer - Gliomas
Breast Cancer - DCIS Breast Cancer
Breast Cancer - Invasive Breast Cancer
Breast Cancer - Metastatic Breast Cancer
Central Nervous System Cancers - Primary Central Nervous System Lymphoma
Cervical Cancer
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colon Cancer
Colorectal Cancer Screening
Distress Management - Distress During Cancer Care
Esophageal Cancer
Gallbladder and Bile Duct Cancers
Graft-Versus-Host Disease
Head and Neck Cancers - Nasopharyngeal Cancer
Head and Neck Cancers - Oral Cancers
Head and Neck Cancers - Oropharyngeal Cancer
Hodgkin Lymphoma
Immunotherapy Side Effects: CAR T-Cell Therapy
Immunotherapy Side Effects: Immune Checkpoint Inhibitors
Kidney Cancer
Liver Cancer
Lung Cancer Screening
Malignant Pleural Mesothelioma
Melanoma
Multiple Myeloma
Mycosis Fungoides/Sézary Syndrome
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
Nausea and Vomiting
Neuroendocrine Tumors
Non-Small Cell Lung Cancer - Early and Locally Advanced
Non-Small Cell Lung Cancer - Metastatic
Ovarian Cancer
Pancreatic Cancer
Peripheral T-Cell Lymphoma
Primary Cutaneous Lymphomas
Prostate Cancer: Advanced Stage
Prostate Cancer: Early Stage
Rectal Cancer
Small Cell Lung Cancer
Soft Tissue Sarcoma
Squamous Cell Skin Cancer
Stomach Cancer
Survivorship Care for Cancer-Related Late and Long-Term Effects
Survivorship Care for Healthy Living
Systemic Mastocytosis
Thyroid Cancer
Uterine Cancer
Waldenström Macroglobulinemia

NCCN.org/patientguidelines

Support provided by
NATIONAL COMPREHENSIVE CANCER NETWORK®